Oct 27, 2010 at 16:25 | Source: CNBC-TV18
Glenmark Pharma reported a net profit of Rs 112 crore as compared to Rs 80.9 crore, a growth of 38.44% on a year-on-year basis. Consolidated net sales rose 23.05% to Rs 741.4 crore from Rs 602.5 crore
Jan 19, 2010 at 19:37 | Source: CNBC-TV18
The recent ruling by the Federal Trade Commission may impact the generics industry. So says Glenn Saldanha, MD and CEO of Glenmark. In an interview with CNBC-TV18, Saldanha spoke about the recent FTC ruling, revenue kickers and out-licensing deals in 2010.
Oct 30, 2009 at 14:02 | Source:
Glenmark Pharmaceuticals declared its second quarter results for the financial year 2010. The companys Q2 consolidated net profit was down at Rs 80.9 crore versus Rs 117.3 crore and its consolidated net sales were up at Rs 590.3 crore versus Rs 559.7 crore
Oct 29, 2009 at 15:43 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, Managing Director and Chief Executive Officer, Glenmark Pharmaceuticals spoke about the companys results.
Sep 15, 2009 at 11:43 | Source: CNBC-TV18
Glennmark Pharmaceutical has raised Rs 413.56 crore via qualified institutional placements through the issue of over 1.87 crore shares. The Pharma has no plans to raise any further equity capital in the parent company but would be raising capital via stake dilution Glenmark generics for further debt repayment.
Jun 24, 2009 at 17:32 | Source: CNBC-TV18
Glenn Saldanha, MD and CEO, Glenmark, said Phase II data of Melogliptin is better than competitors. He said the company is in discussion with various companies to close deal on Melogliptin. "We will be able to close the deal on Melogliptin by CY09 end."
Jun 24, 2009 at 14:39 | Source:
Glenmark Pharma touched an intraday high of Rs 227 and an intraday low of Rs 216.30. At 2:34 pm, the share was quoting at Rs 224.90, up Rs 4.65, or 2.11%. The company's molecule Melogliptin is going to enter in International phase 3 trials by 20909 end, reports CNBC-TV18.
Feb 06, 2009 at 10:47 | Source: CNBC-TV18
Glenn Saldanha, MD and CEO, Glenmark Pharma, said the company will be able to close several out-licensing deals in 12-14 months. He said, We have scaled down base business growth target to about 20%, but we expect significant margin expansion in base business going forward.
Apr 28, 2008 at 14:15 | Source: CNBC-TV18
Glen Saldanha, MD & CEO of Glenmark Pharma said, one of the key factors for the outstanding numbers was a strong US business, which was driving growth and performance. Speaking to CNBC-TV18, he said that out-licensing of some of their NCE pipeline had also contributed significantly to the profits and topline sales.
Feb 01, 2008 at 13:58
Glenmark Pharmaceuticals to get back the global rights to Melogliptin, GRC 8200 from Merck Serono
Follow us on
Available On